Volpara Health Technologies Limited (VHT.AX)

1.1400 0.0000 (0.00%) At close: 04:10PM AEST

Volpara Health Technologies Limited

40 Mercer Street
Levels 14–15 Wellington Central
Wellington 6011
New Zealand
64 4 499 6029
https://www.volparahealth.com

Sector(s): Healthcare
Industry: Health Information Services
Full-time employees: 156

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Teri Jo Thomas	CEO, MD & Director	485.5k	N/A	N/A
Mr. Craig Brett Hadfield	CFO & Company Secretary	350.78k	N/A	N/A
Prof. Nico Karssemeijer	Co-Founder & Member of Scientific Board	N/A	N/A	N/A
Mr. Tana Isaac	Executive Vice President of Product & Technology	N/A	N/A	N/A
Mr. Gareth Beaumont	Chief Information Officer & Chief Information Security Officer	N/A	N/A	N/A
Mr. Frederik Winther Struve B.Sc., J.D.	Joint Company Secretary & General Counsel	N/A	N/A	N/A
Ms. Jill Spear	Executive Vice President of Sales & Customer	N/A	N/A	N/A
Ms. Kathryn Jane Greene	Chief People Officer	N/A	N/A	N/A
Mr. Julian Marshall	Chief Knowledge Officer	373.11k	N/A	N/A
Mr. Mark P. Morris	Executive Vice President	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Volpara Health Technologies Limited provides breast imaging analytics software products in New Zealand. The company offers Volpara Analytics, a software that optimize breast cancer screening operations; Volpara Live, which provides instant patient-based image quality feedback; Volpara Lung, a patient management software that streamlines lung screening workflow; and Volpara Patient Hub, a customizable mammography reporting and patient communications software. It also offers Volpara Risk, an integration with Patient Hub that uses TC8 to calculate patients' risk of developing breast cancer; Volpara Risk Pathways, a program for identifying and managing high-risk breast, lung, ovarian, and colorectal cancer screening patients; Volpara Scorecard, which displays patient breast density and risk insights essential for improved clinical decision-making and early detection; and Volpara Science, an AI-based software that powers Volpara software products; and Volpara Thumbnail, an image-enhanced patient notification letters. In addition, the company provides TruDensity, a Volpara clinical function; TruPGMI, a Volpara clinical function, which uses artificial intelligence to automatically and objectively assess the positioning of the patient and resulting image quality; TruPressure, a Volpara clinical function, which determines whether the compression pressure applied by the radiographer is in the sweet spot that yields quality images, minimal radiation exposure, and the least discomfort; and TruRadDose, a Volpara clinical function which analyses the radiation dose delivered to patients based on their breast density. It operates in North America, the Asia Pacific, Europe, the Middle East, and Africa. Volpara Health Technologies Limited has a strategic relationship with RevealDx. The company was incorporated in 2009 and is headquartered in Wellington, New Zealand.

Corporate governance

Volpara Health Technologies Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.